TGFB1 and chronic kidney disease: Integrin inhibition may provide benefit to COVID-19 patient populations with particularly high levels of TGF-β, such as elderly, White and Hispanic or Latino patients, and patients who receive few medications in the ED, report a high number of symptoms, have a high CSS, and/or have a history of chronic kidney disease.